236 related articles for article (PubMed ID: 33152120)
41. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia.
Bussel JB; Buchanan GR; Nugent DJ; Gnarra DJ; Bomgaars LR; Blanchette VS; Wang YM; Nie K; Jun S
Blood; 2011 Jul; 118(1):28-36. PubMed ID: 21502541
[TBL] [Abstract][Full Text] [Related]
42. Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective.
Yang BB; Doshi S; Arkam K; Franklin J; Chow AT
Clin Pharmacokinet; 2016 Sep; 55(9):1045-58. PubMed ID: 27056734
[TBL] [Abstract][Full Text] [Related]
43. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.
Kantarjian HM; Giles FJ; Greenberg PL; Paquette RL; Wang ES; Gabrilove JL; Garcia-Manero G; Hu K; Franklin JL; Berger DP
Blood; 2010 Oct; 116(17):3163-70. PubMed ID: 20631375
[TBL] [Abstract][Full Text] [Related]
44. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.
Rodeghiero F; Stasi R; Giagounidis A; Viallard JF; Godeau B; Pabinger I; Cines D; Liebman H; Wang X; Woodard P
Eur J Haematol; 2013 Nov; 91(5):423-36. PubMed ID: 23927437
[TBL] [Abstract][Full Text] [Related]
45. Emperipolesis in a patient receiving romiplostim.
Cooper N; Bain BJ
Am J Hematol; 2016 Jan; 91(1):166. PubMed ID: 26407183
[No Abstract] [Full Text] [Related]
46. [Progression of bone marrow fibrosis with reticulin and collagen hyperplasia during treatment with the thrombopoietin receptor agonist romiplostim in a patient with immune thrombocytopenia].
Kirito K; Komatsu N
Rinsho Ketsueki; 2013 Mar; 54(3):295-9. PubMed ID: 23676646
[TBL] [Abstract][Full Text] [Related]
47. Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim.
Kohn B; Bal G; Chirek A; Rehbein S; Salama A
BMC Vet Res; 2016 Jun; 12():96. PubMed ID: 27283401
[TBL] [Abstract][Full Text] [Related]
48. Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience.
Pasquet M; Aladjidi N; Guiton C; Courcoux MF; Munzer M; Auvrignon A; Lutz P; Ducassou S; Leroy G; Munzer C; Leverger G;
Br J Haematol; 2014 Jan; 164(2):266-71. PubMed ID: 24152194
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia.
Michel M; Wasser J; Godeau B; Aledort L; Cooper N; Tomiyama Y; Khellaf M; Wang X
Ann Hematol; 2015 Dec; 94(12):1973-80. PubMed ID: 26341755
[TBL] [Abstract][Full Text] [Related]
50. Deep vein thrombosis associated with a single dose of romiplostim in a high-risk patient.
Przespo E; Elefante A
Am J Health Syst Pharm; 2012 Jan; 69(2):131-3. PubMed ID: 22215358
[TBL] [Abstract][Full Text] [Related]
51. A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia.
Miao J; Leblebjian H; Scullion B; Parnes A
Am J Hematol; 2018 Aug; 93(4):E86-E88. PubMed ID: 29274130
[No Abstract] [Full Text] [Related]
52. Romiplostim: new drug. Thrombocytopenic purpura: for selected patients, with close monitoring.
Prescrire Int; 2009 Dec; 18(104):246. PubMed ID: 20020571
[No Abstract] [Full Text] [Related]
53. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
Mori M; Kato M; Koh K; Hanada R
Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
[TBL] [Abstract][Full Text] [Related]
54. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim.
Cines DB; Gernsheimer T; Wasser J; Godeau B; Provan D; Lyons R; Altomare I; Wang X; Lopez A
Int J Hematol; 2015 Sep; 102(3):259-70. PubMed ID: 26201709
[TBL] [Abstract][Full Text] [Related]
55. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
[TBL] [Abstract][Full Text] [Related]
56. Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials.
Tarantino MD; Despotovic J; Roy J; Grainger J; Cooper N; Beam D; Raj A; Maschan A; Kim J; Eisen M
Pediatr Blood Cancer; 2020 Nov; 67(11):e28630. PubMed ID: 32902132
[TBL] [Abstract][Full Text] [Related]
57. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
Chouhan JD; Herrington JD
Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
[TBL] [Abstract][Full Text] [Related]
58. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia.
Cines DB; Wasser J; Rodeghiero F; Chong BH; Steurer M; Provan D; Lyons R; Garcia-Chavez J; Carpenter N; Wang X; Eisen M
Haematologica; 2017 Aug; 102(8):1342-1351. PubMed ID: 28411254
[TBL] [Abstract][Full Text] [Related]
59. Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia.
Park S; Yoon SS; Lee JH; Park JS; Jang JH; Lee JW
Int J Hematol; 2016 Jan; 103(1):44-52. PubMed ID: 26511480
[TBL] [Abstract][Full Text] [Related]
60. Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia.
Song AB; Goodarzi K; Karp Leaf R; Kuter DJ; Al-Samkari H
Am J Hematol; 2021 Dec; 96(12):1563-1568. PubMed ID: 34453757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]